Diffusion-weighted MRI in the follow-up of chronic periaortitis

Objective:

To evaluate the usefulness of diffusion-weighted MRI (DWI) for the assessment of the intraindividual follow-up in patients with chronic periaortitis (CP) under medication.

Methods:

MRI data of 21 consecutive patients with newly diagnosed untreated disease were retrospectively examined before and after medical therapy, with a median follow-up of 16 weeks. DWI parameters [b800 signal, apparent diffusion coefficient (ADC) values] of the CP and psoas muscle were analysed together with the extent and contrast enhancement. Pre- and post-treatment laboratory inflammation markers were acquired parallel to each MR examination.

Results:

Statistically significant lower b800 signal intensities (p ≤ 0.0001) and higher ADC values (p ≤ 0.0001) were observed after medical treatment within the fibrous periaortic tissue. Extent and contrast enhancement of the CP showed also a statistically significant decrease (p ≤ 0.0001) in the follow-up examinations, while the control parameters within the psoas muscle showed no differences.

Conclusion:

DWI seems to be a useful method for the evaluation of response to treatment without contrast agents. The technique may be helpful in the assessment of disease activity to guide further therapeutic strategies.

Advances in knowledge:

DWI detects significant differences in the intraindividual follow-up of CP under medical therapy.Chronic periaortitis (CP) is a proliferating fibroinflammatory disease of the perivascular retroperitoneal space and aortic wall.^1–4 Owing to adventitial inflammation, some recent theories consider CP as a large vessel vasculitis.⁵ Clinical manifestations of CP include idiopathic retroperitoneal fibrosis, inflammatory aortic aneurysm and perianeurysmal retroperitoneal fibrosis.^2,6,7 The three manifestations with very similar histopathological characteristics are distinguished by the diameter of the abdominal aorta and concomitant ureteral affection.^1,3,7Specific clinical symptoms are caused by extrinsic compression of the ureters or retroperitoneal veins, resulting in hydronephrosis, oliguria, lower extremity oedema and deep vein thrombosis.^1,8Under medical treatment with steroids, CP has a good prognosis.⁷ Today tamoxifen is suggested as a safe and effective therapeutic alternative, and immunosuppressive drugs can be considered in patients with suboptimal responses to these drugs or multiple relapses.^9–11CT and MRI are the modalities of first choice for diagnosis and follow-up of CP.^1,7,12 The fibrotic para-aortic tissue shows significant contrast uptake in gadolinium-enhanced MRI.^12–14 Dynamic contrast-enhanced MRI was suggested for the assessment of the disease activity.^15,16 However, in cases with impaired renal function (e.g. by ureteral compression), gadolinium-independent imaging methods should be preferred owing to the potential development of a nephrogenic systemic fibrosis.¹⁷Diffusion-weighted MRI (DWI) is a non-contrast MR modality that has been successfully applied for the assessment of retroperitoneal masses, inflammatory abdominal aortic aneurysms and for the differentiation between retroperitoneal fibrosis and malignant retroperitoneal neoplasms.^18–21DWI indicates restricted diffusion of water, for example caused by a high cellularity in malignant disease or active inflammation. The apparent diffusion coefficient (ADC) is a quantitative parameter for the level of restricted diffusion, which is calculated from the signals of different diffusion gradients (b-values).²²In the context of untreated CP diffusion-weighted MRI may detect restricted inflammation as a sign of high cellularity caused by active inflammation.There are no data for the evaluation of intraindividual follow-up and the response to treatment by DWI of CP so far. Therefore, the aim of the present study was to analyse differences in DWI signals during follow-up in patients with CP before and after treatment. In addition, we sought to elucidate the potential of DWI in the therapy monitoring of CP.     

Dosimetric evaluation of compensator intensity modulation-based stereotactic body radiotherapy for Stage I non-small-cell lung cancer

Objective:

To evaluate the dosimetry of compensator intensity modulation-based stereotactic body radiotherapy (SBRT) [non-coplanar intensity-modulated radiotherapy (ncIMRT)], its use was compared with that of three-dimensional conformation-based SBRT, for patients with Stage I non-small-cell lung cancer (NSCLC).

Methods:

21 consecutive patients with Stage I NSCLC were treated with ncIMRT or SBRT at Tokyo Medical University. To compare the two techniques, ncIMRT and SBRT plans for each patient were generated, where the planning target volume (PTV) coverages were adjusted to be equivalent to each other. The prescribed dose was set as 75 Gy in 30 fractions. PTV coverage, conformity index, conformation number (CN) and homogeneity index (HI) were used to compare the two strategies.

Results:

There was no statistically significant difference between PTV coverage for the 100%, 95% and 90% dose levels in the SBRT plan and those in the ncIMRT plan. The CN values were 0.53 ± 0.13 in the SBRT plan and 0.72 ± 0.10 in the ncIMRT plan. These values were significantly better than those of the SBRT plan (p < 0.001). The HI in the ncIMRT plan was 1.04 ± 0.03%, which was also significantly better than that of SBRT.

Conclusion:

The ncIMRT plan provided superior conformity and reduced the doses to the lung for patients with Stage I NSCLC.

Advances in knowledge:

The delivery technique with compensator intensity modulation-based SBRT was evaluated. Concerning target motion, this is thought to be more robust and safer than SBRT for early-stage NSCLC.Population-based studies have shown that approximately half of patients with radically treatable Stage I to III non-small-cell lung cancer (NSCLC) have been diagnosed as Stage I.^1,2 Stereotactic body radiotherapy (SBRT) was considered to be a treatment option for patients with Stage I NSCLC who were unsuitable for surgery. In most studies, the SBRT outcomes were comparable with surgery in terms of local control and survival.^3,4 Therefore, the use of SBRT for patients with Stage I NSCLC has gradually increased in number.⁵Videtic et al⁶ first reported excellent local control for Stage I NSCLC when using SBRT based on intensity-modulated radiotherapy (IMRT). Recently, a new type of IMRT named volumetric modulated arc therapy (VMAT) has also been introduced into clinical use. However, the IMRT dose delivery obtained by moving multileaf collimators was not consistent for a moving target.^7–10 By contrast, IMRT using compensated filter was capable of providing constant beams to a moving target and was consistent in the delivered dose distribution.^8,11,12 Furthermore, adjustment of respiratory-induced tumour motion is difficult^13,14 when multileaf collimators were used. We think gated irradiation using IMRT-compensated filter is an ideal method for moving targets. However, when using a compensator intensity modulation-based SBRT [non-coplanar IMRT (ncIMRT)] plan, the dosimetric benefit remains unknown for Stage I NSCLC. Thus, we investigated the benefits of the dose distribution of the ncIMRT plan for Stage I NSCLC via a comparison of the dosimetric parameters.     

Femoral neck shaft angle width is associated with hip-fracture risk in males but not independently of femoral neck bone density

Objective:

To investigate the specificity of the neck shaft angle (NSA) to predict hip fracture in males.

Methods:

We consecutively studied 228 males without fracture and 38 with hip fracture. A further 49 males with spine fracture were studied to evaluate the specificity of NSA for hip-fracture prediction. Femoral neck (FN) bone mineral density (FN-BMD), NSA, hip axis length and FN diameter (FND) were measured in each subject by dual X-ray absorptiometry. Between-mean differences in the studied variables were tested by the unpaired t-test. The ability of NSA to predict hip fracture was tested by logistic regression.

Results:

Compared with controls, FN-BMD (p < 0.01) was significantly lower in both groups of males with fractures, whereas FND (p < 0.01) and NSA (p = 0.05) were higher only in the hip-fracture group. A significant inverse correlation (p < 0.01) was found between NSA and FN-BMD. By age-, height- and weight-corrected logistic regression, none of the tested geometric parameters, separately considered from FN-BMD, entered the best model to predict spine fracture, whereas NSA (p < 0.03) predicted hip fracture together with age (p < 0.001). When forced into the regression, FN-BMD (p < 0.001) became the only fracture predictor to enter the best model to predict both fracture types.

Conclusion:

NSA is associated with hip-fracture risk in males but is not independent of FN-BMD.

Advances in knowledge:

The lack of ability of NSA to predict hip fracture in males independent of FN-BMD should depend on its inverse correlation with FN-BMD by capturing, as the strongest fracture predictor, some of the effects of NSA on the hip fracture. Conversely, NSA in females does not correlate with FN-BMD but independently predicts hip fractures.Hip fracture is the worst osteoporotic fracture with regard to cost^1,2 and adverse consequences,^3,4 so its prevention by checking for the related fracture risk factors is an important goal. Although low bone mineral density (BMD) is generally recognized as the main risk factor for hip fracture,^5,6 there is growing evidence that other bone characteristics, such as proximal femur geometry (PFG) parameters, are implicated in determining the risk profile for hip fracture.^7,8 This evidence, however, mainly derives from studies carried out in females,^9–13 whereas contradictory results characterize studies carried out in males.^14–20 Authors'' opinions seem to vary widely about the ability of the neck shaft angle (NSA), one of the PFG factors, to predict osteoporotic hip fractures in males,^14–16,21 whereas its association with the risk of hip fracture in females^10,11,14,22 is generally accepted. Gender differences in the hip anatomy²³ have been put forward as a possible explanation for the different relationship of NSA with the hip-fracture risk between genders, whereas geographic and racial differences²⁴ among the examined male populations have been advocated as a possible cause of authors'' discrepancies on the relationship between NSA and the hip-fracture risk in males.This topic is therefore still under debate, and further studies are required to clarify the association of the NSA with hip-fracture risk in males. The authors of the current study contribute to this topic by studying the relationship between NSA and the hip fragility fracture in a sample of white Italian males.     

Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumours by diffusion-weighted MRI: a pilot study

The aim of this study was to evaluate prospectively the early treatment response after CT-guided radiofrequency ablation (RFA) of unresectable lung tumours by MRI including diffusion-weighted imaging (DWI). The study protocol was approved by the ethics committee of our hospital and signed consent was obtained from each patient. We studied 17 patients with 20 lung lesions (13 men and 4 women; mean age, 69±9.8 years; mean tumour size, 20.8±9.0 mm) who underwent RFA using a LeVeen electrode between November 2006 and January 2008. MRI was performed on a 1.5T unit before and 3 days after ablation. We compared changes in the apparent diffusion coefficient (ADC) on DWI and response evaluation based on subsequent follow-up CT. 14 of the 20 treatment sessions showed no local progression on follow-up CT, whereas 6 treatment sessions showed local progression (range, 3–17 months; mean, 6 months). For the no-progression group, the ADC pre- and post-RFA were 1.15±0.31 × 10⁻³ mm² s⁻¹ and 1.49±0.24 × 10⁻³ mm² s⁻¹, respectively, while the respective ADC values for those that showed local progression were 1.05±0.27 × 10⁻³ mm² s⁻¹ and 1.24±0.20 × 10⁻³ mm² s⁻¹. The ADC of the ablated lesion was significantly higher than before the procedure (p<0.05). There was a significant difference in the ADC post-RFA between no-progression and local progression groups (p<0.05). Our prospective pilot study showed that the ADC without local progression was significantly higher than with local progression after RFA, suggesting that the ADC can predict the response to RFA for lung tumours.After the first report in 2000 [1], lung radiofrequency ablation (RFA) is now considered effective in the treatment of lung cancer, which is traditionally considered unresectable owing to compromised pulmonary function or advanced age. In general, complications associated with lung RFA are minimal, and favourable local control has been reported in a number of studies of tumours with a diameter of 30 mm or less [1–5]. However, only a limited number of studies have been published regarding the treatment outcome after lung RFA [6–10]. In this process, a layer of normal lung tissue surrounding the tumour is also ablated as a safety margin. Inevitably, the ablated lesion depicted on a CT scan immediately after the procedure is larger than the original tumour mass. However, this region of increased density shrinks with time, but follow-up CT may still show the ablated lesion being as big as, or larger than, the tumour size before the procedure [6, 7]. Thus, radiologists sometimes encounter difficulty in distinguishing scarred tissue from a tumour residue/local progression when the size of the lesion remains the same. Accurate assessment of RFA outcome would have important consequences, as recurrent tumours can be treated again if detected at an early stage. Different modalities of early-stage follow-up examination, such as contrast-enhanced CT [8] and fluorodeoxyglucose positron emission tomography (FDG–PET), have been of great interest and their usefulness has been reported by several groups [9, 10]. Another approach — MR diffusion-weighted imaging (DWI) — which is based on the measurement of motion of water molecules, has also been reported as a non-invasive evaluation modality [11–19]. In this method, the apparent diffusion coefficient (ADC) represents the water content and distribution, the cellular density and the cell membrane integrity, suggesting the potential usefulness of an ADC map for estimating tumour viability. Indeed, DWI has been successfully used to assess the efficacy of radiotherapy [11, 12], chemotherapy [13–15] and transcatheter arterial embolisation [16, 17]. To our knowledge, only two studies have reported the use of DWI to evaluate the therapeutic outcome of RFA [18, 19]. A previous study reported that the ADC value of an ablated rabbit tumour model (VX2 tumour) was significantly higher than that of untreated tumours, and that FDG uptake on micro-PET for small animals with ablated tumours was significantly lower than for untreated tumours. These results indicate that DWI at 2 days and FDG–PET at 3 days after RFA are both potentially feasible modalities for monitoring the early effects of the procedure [19]. In this study, we calculated the ADC in tumour lesions before and after clinical lung RFA and examined the usefulness of DWI in the early detection of tumour response to RFA.     

Correlation of the apparent diffusion coefficiency values on diffusion-weighted imaging with prognostic factors for breast cancer

Objective

The aim of this study was to correlate the apparent diffusion coefficient (ADC) value of breast cancer with prognostic factors.

Methods

335 patients with invasive ductal carcinoma not otherwise specified (IDC NOS) and ductal carcinoma in situ (DCIS) who underwent breast MRI with diffusion-weighted imaging were included in this study. ADC of breast cancer was calculated using two b factors (0 and 1000 s mm^–2). Mean ADCs of IDC NOS and DCIS were compared and evaluated. Among cases of IDC NOS, mean ADCs were compared with lymph node status, size and immunochemical prognostic factors using Student''s t-test. ADC was also correlated with histological grade using the Kruskal–Wallis test.

Results

Mean ADC of IDC NOS was significantly lower than that of DCIS (p<0.001). However, the mean ADC of histological grade of IDC NOS was not significantly different (p=0.564). Mean ADC of oestrogen receptor (ER)-positive or progesterone receptor (PR)-positive cancer was significantly lower than that of ER-negative or PR-negative cancer (p=0.003 vs p=0.032). Mean ADC of Ki-67 index-positive cancer was significantly lower than that of Ki-67 index-negative cancer (p=0.028). Mean ADC values of cancers with increased microvascular density (MVD) were significantly lower than those of cancer with no MVD increase (p=0.009). No correlations were observed between mean ADC value and human growth factor receptor 2 expression, tumour size and lymph node metastasis.

Conclusion

Low ADC value was correlated with positive expression of ER, PR, increased Ki-67 index, and increased MVD of breast cancer.Breast MRI is an established supplemental technique to mammography and ultrasonography for evaluation of suspicious breast lesions. Diffusion-weighted MRI (DWI) has recently been integrated into the standard breast MRI for discrimination of benign and malignant breast lesions obtained with dynamic contrast-enhanced MRI [1-13]. DWI is a non-invasive technique that represents the biological character of the mainly Brownian movement of protons in bulk water molecules in vivo. Apparent diffusion coefficient (ADC) values are quantified by measurement of mean diffusivity along three orthogonal directions, which are affected by cellularity of the tissue, fluid viscosity, membrane permeability and blood flow [7,9-11]. Microstructural characteristics, including water diffusion and blood microcirculations in capillary networks, were associated with ADC value. Decreased movement of molecules in highly cellular tissue showed correlation with a low ADC value [3,4]. Several studies of DWI of the breast have reported significantly lower ADC values in malignant tumours, compared with benign breast lesions and normal tissue [1-3,5-11,14]. Classic prognostic markers, including tumour size and grade, and lymph node status in patients with breast cancer, and molecular markers, including oestrogen receptor (ER), progesterone receptor (PR), Ki-67 index, human growth factor receptor 2 (HER2) protein and angiogenic molecular markers, have been reported [1,15,16]. Few studies have examined the correlation between ADC values and prognostic factors [1,8]. The purpose of this study is to compare ADC values of DWI of breast cancer with prognostic factors.     

The challenge of segmental small bowel motility quantitation using MR enterography

Objective:

Analysis of “cine” MRI using segmental regions of interest (ROIs) has become increasingly popular for investigating bowel motility; however, variation in motility in healthy subjects both within and between scans remains poorly described.

Methods:

20 healthy individuals (mean age, 28 years; 14, males) underwent MR enterography to acquire dynamic motility scans in both breath hold (BH) and free breathing (FB) on 2 occasions. Motility data were quantitatively assessed by placing four ROIs per subject in different small bowel segments and applying two measures: (1) contractions per minute (CPM) and (2) Jacobian standard deviation (SD) motility score. Within-scan (between segment) variation was assessed using intraclass correlation (ICC), and repeatability was assessed using Bland–Altman limits of agreement (BA LoA).

Results:

Within-scan segmental variation: BH CPM and Jacobian SD metrics between the four segments demonstrated ICC R = 0.06, p = 0.100 and R = 0.20, p = 0.027 and in FB, the CPM and Jacobian SD metrics demonstrated ICC R = −0.26, p = 0.050 and R = 0.19, p = 0.030. Repeatability: BH CPM for matched segments ranged between 0 and 14 contractions with BA LoA of ±8.36 and Jacobian SD ranged between 0.09 and 0.51 with LoA of ±0.33. In FB data, CPM ranged between 0 and 10 contractions with BA LoA of ±7.25 and Jacobian SD ranged between 0.16 and 0.63 with LoA = ±0.28.

Conclusion:

The MRI-quantified small bowel motility in normal subjects demonstrates wide intersegmental variation and relatively poor repeatability over time.

Advances in knowledge:

This article presents baseline values for healthy individuals of within- and between-scan motility that are essential for understanding how this process changes in disease.Dynamic “cine” MRI acquired during MR enterography is increasingly utilized to assess bowel motility in a range of conditions, notably inflammatory bowel disease and enteric dysmotility syndromes.^1–4 Analysis of the data remains primarily subjective in clinical routine, but the ability to apply quantitative techniques makes this a potentially powerful methodology to explore gastrointestinal physiology in disease as well as an emerging application as a biomarker for drug efficacy.^5–7Despite the growing literature, a consensus has yet to be reached as to the best method of quantitatively analysing small bowel data and indeed a range of motility metrics are proposed.^2,3,8–12 The most commonly used metric is the change in luminal diameter at a fixed anatomical position through the time series. By tracking bowel diameter, a characteristic curve can be produced with the number of contractions expressed per minute (CPM) to give an intuitive and broadly accepted metric for small bowel motility (SBM).^{2–4,9,11,13–15} To date, several studies have reported a relationship between CPM and dysmotility in disease, either compared with a histopathological standard or “normal” reference bowel loops.^2–4,12 An array of additional metrics derived both from bowel diameter measures and more abstract processing techniques have further been implemented with varying degrees of effectiveness in disease and health.^{2,4,5,8,10,14,16}Although intuitively attractive, the robustness of assessing overall enteric motility using only an isolated loop of bowel has received relatively little attention to date irrespective of the precise metric applied. It is unclear how representative the selected bowel loops are of overall SBM and if normal motility intrinsically differs between bowel segments, for example, between the jejunum and ileum. Furthermore, the repeatability of single loop metrics, even in normal individuals, is not well described, knowledge of which is vital if segmental analysis is to be used to diagnose, guide treatment and monitor enteric pathology.The purpose of this study is to explore segmental variation in SBM in healthy volunteers measured using two commonly reported small bowel metrics [CPM and Jacobian standard deviation (SD)] looking at (1) within-scan motility variation between different segments and (2) between-scan variation (repeatability) across two time points.     

Diffusion-weighted MRI as a potential imaging biomarker reflecting the metastatic potential of upper urinary tract cancer

Objective:

To evaluate the role of diffusion-weighted MRI (DW-MRI) as an imaging biomarker for upper urinary tract cancer (UUTC) that has already metastasized or will metastasize soon.

Methods:

61 patients clinically diagnosed with UUTC were prospectively enrolled in this study. All the patients underwent MRI, including DW-MRI, prior to any interventions. Correlations between apparent diffusion coefficient (ADC) and other clinicopathological variables, including metastasis-free survival, were analysed.

Results:

Median follow-up period was 938 days. Of the 61 patients, 12 had any metastases at the initial diagnosis. 11 patients developed metastases during the follow-up period. These 23 patients were categorized as “Metastatic”. Of the remaining 38 patients, 35 with a follow-up period longer than 400 days were categorized as “Localized”. ADC was significantly lower in the Metastatic category than in the Localized (p = 0.0002) category. Multivariate analysis of pre-operative variables identified ADC (cut-off value, 1.08 × 10⁻³ mm² s⁻¹) and clinical T stage based on T₂ weighted MRI as an independent predictive factor of metastatic UUTC. 46 patients without any metastases during the initial diagnosis were stratified into a high-risk group (16 patients with low ADC and clinical T3–4) and a low-risk group (30 patients with high ADC or clinical Ta-2). The 3-year metastasis-free survivals were 45% and 93%, respectively.

Conclusion:

In the current study, UUTC with lower ADC value is more likely to have metastatic potential. Incorporating ADC with clinical T stage helps to differentiate metastatic UUTC at the initial diagnosis.

Advances in knowledge:

DW-MRI is a potential imaging biomarker reflecting metastatic propensity of UUTC.Upper urinary tract cancer (UUTC) is a potentially lethal disease. The prognosis remains poor even when standard care, radical nephroureterectomy (RNU) is performed, and almost one-third of the patients die within 5 years.^1–3 In the management of localized UUTC, adjuvant chemotherapy has no impact on survival, particularly owing to the impaired post-surgical renal function or comorbidity.⁴ However, neoadjuvant chemotherapy, which showed a survival benefit in bladder cancer,⁵ may have a similar benefit in UUTC.Neoadjuvant chemotherapy can be considered an option for locally advanced disease at diagnosis. Two nomograms are available for predicting locally advanced UUTC in the pre-operative setting: one includes tumour histological grade, architecture and location and the other includes histological grade and radiological clinical stage.^6,7 “Localized disease” at the initial diagnosis that will develop metastasis soon after RNU can also be a candidate for neoadjuvant chemotherapy. However, identifying these occult or developing metastases pre-operatively remains a challenge.Diffusion-weighted MRI (DW-MRI) is a functional imaging technique that reveals physiological information by quantifying the diffusion of water molecules in tissues.⁸ The extent of water diffusion is quantified as the apparent diffusion coefficient (ADC). In 2009, a consensus meeting was held on the use of DW-MRI as a cancer imaging biomarker.⁹ An extraordinary opportunity for DW-MRI to evolve into a clinically valuable imaging tool was indicated. This imaging technique has been incorporated into general oncological imaging practices, including tissue characterization, monitoring the treatment response and predicting treatment outcome, in various cancers.^8,10–14Previous studies demonstrated the role of the ADC as a marker for the biological aggressiveness of UUTC by showing a correlation of the ADC with the histological grade and the Ki-67 labelling index.^14,15 Furthermore, the ADC was significantly associated with the cancer-specific survival after RNU.¹⁵ Therefore, we hypothesized that the ADC can be used as a marker to reflect the metastatic potential of UUTC, as has been reported in bladder cancer.¹⁶ The aim of this study is to show that the ADC can predict UUTC that has already metastasized or will metastasize soon. We first evaluated ADC values of the biologically metastatic UUTC and non-metastatic UUTC. Secondarily, we analysed the potential of the ADC to predict the development of metastasis.     

Multidetector CT imaging features of solid pseudopapillary tumours of the pancreas in male patients: distinctive imaging features with female patients

Objective:

To describe multidetector CT imaging features of solid pseudopapillary tumours (SPTs) in male patients and to compare these imaging features with those found in female patients.

Methods:

The institutional review board approved this retrospective study. We included the CT images of 72 patients (M:F = 12:60; mean age, 35.0 years) diagnosed with SPT by histology. CT images were reviewed on the following: location of the tumour, maximal diameter, shape, margin and the fraction of the tumour composition. Statistical differences in CT imaging features were analysed.

Results:

Male patients with SPTs were significantly older than female patients (42.4 years vs 33.4 years, p = 0.0408) and the mean size of the SPTs in male patients was larger (6.3 cm vs 4.6 cm, p = 0.0413) than that of SPTs in female patients. Lobulated shape of the SPTs was most frequent in male patients, whereas oval shape was most frequent in female patients (p = 0.0133). SPTs in male patients tended to have a solid component (p = 0.0434). Progressive enhancement in the solid portion of the tumour was seen in 9 (81.8%) of 11 SPTs in male patients and in 30 (79.0%) of 38 SPTs in female patients on multiphasic CT.

Conclusion:

The imaging features of SPTs in male patients usually appeared as a somewhat large-sized solid mass with a lobulated margin and progressive enhancement. These imaging features may help to differentiate SPTs from other pancreatic tumours for their proper management.

Advances in knowledge:

SPTs in male patients appear as somewhat large-sized solid masses with lobulated margins, and this form occurs more frequently in older male patients than in female patients.Solid pseudopapillary tumour (SPT) of the pancreas is a rare low-grade malignant neoplasm accounting for only 1–2% of all pancreatic tumours.^1–3 Synonyms for this neoplasm include solid and cystic tumours, solid and papillary epithelial neoplasms, solid cystic papillary tumour, papillary cystic neoplasm, papillary cystic epithelial neoplasm, papillary cystic tumour or Frantz''s tumour.^3,4SPT is known to occur preferentially in young females and has a favourable prognosis. The characteristic imaging features of SPTs include encapsulation, solid and cystic components and peripheral calcification.^1,3,4 Although the imaging characteristics of SPTs have been well described in recent years,^3,5 it remains uncertain if the features of SPT occurring in males differ from those in females.Machado et al⁶ and Takahashi et al⁷ described distinctive clinicopathological characteristics of SPTs occurring in males. The purpose of this study was to describe multidetector CT (MDCT) imaging features of SPTs in male patients and to compare these features with those of female patients.     

125I particle implantation combined with chemoradiotherapy to treat advanced pancreatic cancer

Objective:

To evaluate the therapy effects of ¹²⁵I implantation combined with chemoradiotherapy on pancreatic cancer patients.

Methods:

30 patients with Stage III or IV pancreatic cancer were equally divided into two groups (control and treatment group). The patients in the treatment group (nine males, six females) received chemotherapy in the first week and ¹²⁵I implantation in the third week, followed by combined chemoradiotherapy in the fifth week. The patients in the control group (10 males, 5 females) received the same treatment except ¹²⁵I implantation. The therapy in the control group and treatment group was repeated every 4 weeks.

Results:

The median conformal radiotherapy dose in the treatment group (30.62 Gy) was significantly lower than that in the control group (47.86 Gy). The total radiation dose was 88.71 ± 27.39 Gy, and the surface activity was 0.6 mCi in the treatment group. After treatment, the average tumour size decreased both in the treatment group [9.17 cm², 95% confidence interval (CI): 5.60–12.74, p < 0.001] and in the control group (4.54 cm², 95% CI: 2.74–6.35, p < 0.001). The median survival time in the treatment group was 14 months (95% CI: 12.215–14.785) and in the control group was 12 months (95% CI: 10.884–13.116). There was no statistical significance in survival rates between the two groups (χ² = 0.908, p = 0.341).

Conclusion:

¹²⁵I implanted into tumour combined with chemoradiotherapy has higher local control rate of advanced pancreatic cancer than chemoradiotherapy.

Advances in knowledge:

We combined chemoradiotherapy with ¹²⁵I implantation to treat advanced pancreatic cancer and obtained a higher local control rate and better quality of life than when using chemoradiatherapy alone.Pancreatic cancer is currently one of the most intractable cancers with high and continually rising mortality in China.¹ The main risk factors are smoking, age and some genetic disorders, although the primary causes are poorly understood.² Pancreatic cancer causes no early symptoms, so the majority of patients are diagnosed as having advanced cancer with rapid progression when they come to the hospital.³ Thus, patients miss the opportunity for tumour resection when first diagnosed. Even if the cancer is discovered early, only 20% of patients can undergo surgical excision, whereas the other 80% cannot.² For patients who have undergone radical excision, the 5-year survival rate is just 20–25%.^4–9Advanced pancreatic cancer, according to the TNM stage of pancreatic carcinoma by the American Joint Committee on Cancer (AJCC),¹⁰ includes Stages III and IV, and pancreatectomy is not well accepted.¹¹ It is reported that approximately 40% of pancreatic cancer patients present with locally advanced, non-metastatic disease.¹² Local lesions play a vital role in a patient''s survival.^13–16 The aim of advanced pancreatic cancer treatment is to enhance local lesion control and improve the quality of life (QOL).^17,18Gemcitabine is a type of pyrimidine analogue, which acts as a ribonucleoside reductase inhibitor and destroys cells and terminates the DNA chains. It has been approved by the US Food and Drug Administration as a gold standard agent in chemotherapy¹⁹ for the treatment of cancer, especially for advanced pancreatic cancer.²⁰ Currently, the major therapy is comprehensive treatment, namely chemoradiotherapy, which is superior to either radiotherapy²¹ or chemotherapy.²² But the overall survival time is not prolonged by chemoradiotherapy in advanced pancreatic cancer compared with single-agent gemcitabine.²³ The 5-year survival rate is still <5%.²⁴ However, interstitial implantation of radioactive seeds (brachytherapy) combined with conformal radiotherapy (external beam radiation therapy) has a good effect for local control of pancreatic cancer.^{25,26 125}I particles are reported to be the most commonly used for brachytherapy because of their long half-life and short radiation distance.²⁷ Therefore, we infer that ¹²⁵I implantation combined with chemoradiation may obtain better curative effects.In this study, we compared the local control rate, pain relief and survival rate of 30 patients with advanced pancreatic cancer who were treated with or without ¹²⁵I implantation combined with chemoradiotherapy in our hospital during October 2006 to January 2012. We expected that the implantation of ¹²⁵I particles could be an efficient therapy for patients with advanced pancreatic cancer.     

Primary vaginal cancer: role of MRI in diagnosis,staging and treatment

Primary carcinoma of the vagina is rare, accounting for 1–3% of all gynaecological malignancies. MRI has an increasing role in diagnosis, staging, treatment and assessment of complications in gynaecologic malignancy. In this review, we illustrate the utility of MRI in patients with primary vaginal cancer and highlight key aspects of staging, treatment, recurrence and complications.The incidence of primary vaginal cancer increases with age, with approximately 50% of patients presenting at age greater than 70 years and 20% greater than 80 years.¹ Around 2890 patients are currently diagnosed with vaginal carcinoma in the USA each year, and almost 30% die of the disease.² The precursor for vaginal cancer, vaginal intraepithelial neoplasia (VAIN) and invasive vaginal cancer is strongly associated with human papillomavirus (HPV) infection (93%).^3,4 In situ and invasive vaginal cancer share many of the same risk factors as cervical cancer, such as tobacco use, younger age at coitarche, HPV and multiple sexual partners.^5–7 In fact, higher rates of vaginal cancer are observed in patients with a previous diagnosis of cervical cancer or cervical intraepithelial neoplasia.^7,8As is true for other gynaecologic malignancies, vaginal cancer diagnosis and staging rely primarily on clinical evaluation by the International Federation of Gynecology and Obstetrics (FIGO).⁹ Pelvic examination continues to be the most important tool for evaluating local extent of disease, but this method alone is limited in its ability to detect lymphadenopathy and the extent of tumour infiltration. Hence, FIGO encourages the use of imaging. Fluorine-18 fludeoxyglucose-positron emission tomography (¹⁸F-FDG-PET), a standard imaging tool for staging and follow-up in cervical cancer, can also be used for vaginal tumours, with improved sensitivity for nodal involvement compared to CT alone.¹⁰ In addition to staging for nodal and distant disease, CT [simulation with three dimensional (3D) conformations] is particularly useful for treatment planning and delivery of external beam radiation. MRI, with its excellent soft tissue resolution, is commonly used in gynaecologic malignancies and has been shown to be accurate in diagnosis, local staging and spread of disease in vaginal cancer.^11,12 While no formal studies are available for vaginal cancer, in cervical cancer MRI actually alters the stage in almost 30% of patients.^13–15Treatment planning in primary vaginal cancer is complex and requires a detailed understanding of the extent of disease. Because vaginal cancer is rare, treatment plans remain less well defined, often individualized and extrapolated from institutional experience and outcomes in cervical cancer.^1,16–19 There is an increasing trend towards organ preservation and treatment strategies based on combined external beam radiation and brachytherapy, often with concurrent chemotherapy,^14,20,21 surgery being reserved for those with in situ or very early-stage disease.²² Increasing utilization of MR may provide superior delineation of tumour volume, both for initial staging and follow-up, to allow for better treatment planning.²³     

Repeatability of quantitative metrics derived from MR diffusion tractography in paediatric patients with epilepsy

Objective:

To quantify the test–retest repeatability of mean diffusivity (MD) and fractional anisotropy (FA) derived from diffusion tensor imaging (DTI) tractography in a cohort of paediatric patients with localization-related epilepsy.

Methods:

30 patients underwent 2 DTI acquisitions [repetition time/echo time (ms), 7000/90; flip, 90°; b-value, 1000 s mm⁻²; voxel (mm), 2 × 2 × 2]. Two observers used Diffusion Toolkit and TrackVis (www.trackvis.org) to segment and analyse the following tracts: corpus callosum, corticospinal tracts, arcuate fasciculi, inferior longitudinal fasciculi and inferior fronto-occipital fasciculi. Mean MD and mean FA were calculated for each tract. Each observer independently analysed one of the DTI data sets for every patient.

Results:

Segmentation identified all tracts in all subjects, except the arcuate fasciculus. There was a highly consistent relationship between repeated observations of MD (r = 0.993; p < 0.0001) and FA (r = 0.990; p < 0.0001). For each tract, coefficients of variation ranged from 0.9% to 2.1% for MD and from 1.5% to 2.8% for FA. The 95% confidence limits (CLs) for change ranged from 2.8% to 6% for MD and from 4.3% to 8.6% for FA. For the arcuate fasciculus, Cohen''s κ for agreement between the observers (identifiable vs not identifiable) was 1.0.

Conclusion:

We quantified the repeatability of two commonly utilized scalar metrics derived from DTI tractography. For an individual patient, changes greater than the repeatability coefficient or 95% CLs for change are unlikely to be related to variability in their measurement.

Advances in knowledge:

Reproducibility of these metrics will aid in the design of future studies and might one day be used to guide management in patients with epilepsy.Epilepsy is a common neurological condition defined by recurrent unprovoked seizures that affects 1% of the population, including 1 in 200 children.^1,2 Unlike in adults, developmental lesions predominate as the source of seizures in children; in particular, focal cortical dysplasia is the most common anatomical substrate for intractable epilepsy in the paediatric population.³ A high proportion of epilepsies occurring in the setting of cortical malformations are pharmacoresistant,⁴ highlighting the importance of alternative management strategies. In appropriately selected patients who fail medical management, surgical resection of the dysplastic cortex can be curative. In such cases, pre-operative identification and complete resection of the structural lesion are important prognostic factors.^5,6 Decision making surrounding the pursuit of invasive alternatives is rarely straightforward, however, and in practice relies heavily on supplementary information provided by novel diagnostic techniques.Although surgical management is an attractive option for many patients with focal seizures, medical therapy continues to be adopted as the “safe” strategy in a significant portion of this population. However, there is good evidence to suggest that ongoing seizures and treatment with antiseizure medication might be associated with progressive alterations in white matter integrity.^7–9 Furthermore, these same ongoing processes can contribute to progressive functional decline.^10,11 As such, the ability to confidently identify progression of network alterations in an individual patient with epilepsy, whether on the basis of ongoing seizure activity, antiseizure medication or both, would be of great value to informed decision making surrounding potential surgical intervention.With the advent of diffusion-weighted imaging (DWI), the microstructural properties of a tissue of interest can be non-invasively probed at a spatial scale that is otherwise unattainable using even the most advanced structural MR techniques. Diffusion tensor imaging (DTI) is a variation on the theme of DWI, which quantifies water motion in three orthogonal dimensions and, therefore, is better able to capture the anisotropic tendencies of diffusion in highly organized tissues, such as cerebral white matter.¹² Numerous scalar metrics can be derived from the tensor; the most commonly referenced are mean diffusivity (MD) and fractional anisotropy (FA). MD provides a measure of overall incoherent motion within a voxel without regard for direction and reflects tissue organization at the cellular level.¹³ Increased MD is a common manifestation of white matter pathology of diverse aetiology.^14–16 By contrast, FA provides a measure of the degree to which a single direction of water motion dominates overall diffusivity in a voxel. As such, FA has been shown to be a relatively robust measure of white matter integrity.^17–21 Diffusion tractography is an extension of DTI in which the directional tendencies of water diffusion are used to create three-dimensional representations of white matter tracts based on their structural coherence.^22,23 In many instances, the functional role of the constructed pathways is at least in part known, which enables assessment of brain parenchymal abnormalities in terms of functional systems.^16,24DTI and diffusion tractography already occupy a prominent place in epilepsy research, and they are increasingly used to guide clinical management of epilepsy patients.^7,25–30 Although preliminary results are promising, a thorough understanding of the test–retest reproducibility of metrics derived from DTI will be crucial to the widespread application of this technique. Such knowledge would inform the design of both cross-sectional and longitudinal studies, including appropriate sample size selection. Furthermore, the clinical utility of such quantitative techniques will be predicated on an understanding of their intrinsic variability at the level of the individual. In particular, an understanding of what represents true difference at the individual level will be required to ascribe significance to changes in these metrics that occur in an individual patient. To date, however, the reproducibility of quantitative metrics derived from tractography has not been widely studied and, in particular, there are very few data from either the paediatric or epilepsy populations.³¹ The goal of this study, therefore, was to measure the repeatability of MD and FA derived from DTI tractography in a cohort of paediatric patients with localization-related epilepsy.     

Investigation into the radiobiological consequences of pre-treatment verification imaging with megavoltage X-rays in radiotherapy

Objective:

The aim of this study was to investigate the effect of pre-treatment verification imaging with megavoltage X-rays on cancer and normal cell survival in vitro and to compare the findings with theoretically modelled data. Since the dose received from pre-treatment imaging can be significant, the incorporation of this dose at the planning stage of treatment has been suggested.

Methods:

The impact of imaging dose incorporation on cell survival was investigated by clonogenic assay of irradiated DU-145 prostate cancer, H460 non-small-cell lung cancer and AGO-1522b normal tissue fibroblast cells. Clinically relevant imaging-to-treatment times of 7.5 and 15 min were chosen for this study. The theoretical magnitude of the loss of radiobiological efficacy due to sublethal damage repair was investigated using the Lea–Catcheside dose protraction factor model.

Results:

For the cell lines investigated, the experimental data showed that imaging dose incorporation had no significant impact on cell survival. These findings were in close agreement with theoretical results.

Conclusion:

For the conditions investigated, the results suggest that allowance for the imaging dose at the planning stage of treatment should not adversely affect treatment efficacy.

Advances in knowledge:

There is a paucity of data in the literature on imaging effects in radiotherapy. This article presents a systematic study of imaging dose effects on cancer and normal cell survival, providing both theoretical and experimental evidence for clinically relevant imaging doses and imaging-to-treatment times. The data provide a firm foundation for further study into this highly relevant area of research.Radiotherapy is in a period of rapid scientific and clinical development. With the introduction of adaptive radiotherapy¹ and the increasing use of high-precision techniques,² there has been an increased requirement for verification imaging. Verification imaging can be carried out using megavoltage portal beams, kilovoltage planar fields or cone beam CT (CBCT) using kilovoltage or megavoltage beams. Dependent on the imaging technique employed, the dose required to acquire an image of adequate quality can vary significantly. Whilst doses ranging from a few centigrays to 10 cGy are required for megavoltage portal imaging and CBCT, doses in the order of megagrays are typically required to obtain an image of adequate quality using kilovoltage planar imaging.³ The choice of imaging modality is dictated by the available technology, with megavoltage portal imaging being the most established imaging option. However, with the addition of on-board kilovoltage imaging systems, kilovoltage imaging options are becoming much more widespread both for their improved image contrast and reduced patient dose.⁴Associated with this increasing imaging dose burden are concerns regarding the increased risk of deterministic and stochastic effects due to increased radiation exposure.^3,5–7 Whilst it is important to quantitatively determine the long-term effects of increased concomitant exposures, it is equally important to determine any potential changes to the effectiveness of the therapeutic dose.^5,8–10Low-dose biological phenomena such as adaptive responses^11–13 and bystander signalling^14–17 hold the potential to significantly alter the response of cells to radiation and thus treatment efficacy. However, since these effects tend to occur over a period of hours, it is unlikely that they will have any significant impact with regard to imaging in the treatment room.¹⁸ By contrast, sublethal damage repair that can occur over a period of minutes may be of significance in radiotherapy when the dose delivered from imaging beams is incorporated with the prescribed therapeutic dose at the treatment planning stage.^9,10,19–22The effect of imaging dose incorporation was previously reported in a preliminary study by Yang et al.¹⁰ In particular, they showed an unexpected 12.6% increase in cell survival when H460 cells were exposed to a pre-treatment imaging dose of 5 cGy followed by a therapeutic dose of 200 cGy, they attributed their findings to increased cell proliferation. The results suggest that the delivery of a fraction of the therapeutic dose by imaging beams presents a potential issue since the time from imaging to delivery of the treatment can be of the order of 5–20 min, having a negative impact on treatment efficacy owing to low-dose biological phenomena¹⁶ or sublethal damage repair that may be initiated during this time.^9,19 Although the need for imaging dose incorporation is justified, the potential to affect treatment efficacy should be determined.To investigate the radiobiological impact of imaging dose incorporation, a series of experiments were conducted in vitro, where the imaging doses were incorporated with the prescribed treatment dose for different human cell lines. As megavoltage portal imaging is the most widely used type of imaging for verification and as it delivers a higher dose, the study was carried out using 6 MV beams for both the imaging and treatment components. The theoretical magnitude of this effect and its impact on cell survival was quantified using radiobiological modelling based on the Lea–Catcheside dose protraction factor²³ as a comparison to the experimental data.     

Walking on thin ice! Identifying methamphetamine “drug mules” on digital plain radiography

Objective:

The purpose of this study was to retrospectively evaluate the sensitivity, specificity and accuracy of identifying methamphetamine (MA) internal payloads in “drug mules” by plain abdominal digital radiography (DR).

Methods:

The study consisted of 35 individuals suspected of internal MA drug containers. A total of 59 supine digital radiographs were collected. An overall calculation regarding the diagnostic accuracy for all “drug mules” and a specific evaluation concerning the radiological appearance of drug packs as well as the rate of clearance and complications in correlation with the reader''s experience were performed. The gold standard was the presence of secured drug packs in the faeces.

Results:

There were 16 true-positive “drug mules” identified. DR of all drug carriers for Group 1 (forensic imaging experienced readers, n = 2) exhibited a sensitivity of 100%, a mean specificity of 76.3%, positive predictive value (PPV) of 78.5%, negative predictive value (NPV) of 100% and a mean accuracy 87.2%. Group 2 (inexperienced readers, n = 3) showed a lower sensitivity (93.7%), a mean specificity of 86%, a PPV of 86.5%, an NPV of 94.1% and a mean accuracy of 89.5%. The interrater agreement within Group 1 was 0.72 and within Group 2 averaged to 0.79, indicating a fair to very good agreement.

Conclusion:

DR is a valuable screening tool in cases of MA body packers with huge internal payloads being associated with a high diagnostic insecurity. Diagnostic insecurity on plain films may be overcome by low-dose CT as a cross-sectional imaging modality and addressed by improved radiological education in reporting drug carriers on imaging.

Advances in knowledge:

Diagnostic signs (double-condom and halo signs) on digital plain radiography are specific in MA “drug mules”, although DR is associated with high diagnostic insecurity and underreports the total internal payload.For the past decade, significant worldwide manufacturing of amphetamine-type stimulants has been reported to the United Nations Office on Drugs and Crime, Vienna, Austria, with a predominance of methamphetamine (MA) and its derivatives, which are also known as “syabu” or “ice”, throughout East and South East Asia.¹ In this region, the use of this synthetic drug is more prevalent than that of cocaine or heroin, which are more common in relatively developed areas, such as Europe and the USA.² During the course of this development, an increase in the number of drug carriers being intercepted by law enforcement at the borders of Malaysia has been observed. Drug carriers or “drug mules” are generally referred to as a human harbouring internal illicit drug packet(s). Internal body concealment of illegal drugs is one of the methods used to smuggle this illicit drug across the border.^3,4 “Drug mules” are generally known as body packers.^5,6 However, for correct terminology, one should differentiate between the terms body packer, body pusher and body stuffer. A body packer swallows a large amount of specially prepared drug packets to smuggle the packets in their gastrointestinal tract across a national border.^5,6 A body pusher hides a few containers in easily accessible body cavities, such as the rectum or vagina. Body stuffers, including traffickers and users, ingest intentionally small amounts of loosely wrapped drug pellets (typically initially hidden in the mouth), usually immediately before an unexpected encounter with law enforcement.^5–10The generally accepted radiological examination is a plain abdominal radiograph in the supine projection.^4–6 This technique is widely available at a low cost and is a simple method of detecting drug-filled packets within the alimentary tract. Radiation exposure to the patient is relatively moderate. In the literature, the detection rate for drug-filled packets is highly variable, and sensitivities from 58.3% to 90% have been reported.^4,5,11 Hence, plain abdominal radiography is a flawed screening method for identifying “drug mules”. Examining the bowel for foreign bodies, such as drug containers with variable sizes and radiodensities, is problematic, even for an experienced radiologist because the drug-filled packets may have an appearance similar to that of stool and gas and may be superimposed. Specific appearances described in the literature, such as the “double-condom”, “halo” and “rosette” signs, may be diagnostic for drug packages but are not necessarily so.^{4–6,11–13} Other modalities employed worldwide for the identification of body packers include CT, ultrasound, MRI and low-dose linear slit digital radiography (LSDR or LODOX®; Lodox Systems, Johannesburg, South Africa).^4,5,14–18Recent research has mainly concentrated on cocaine and heroin drug trafficking, which occurs predominantly in Western countries.^{3,4,6,7,11,14,19} There is little research on the accuracy of plain abdominal radiography in MA drug carriers, although there has been a significant increase of MA in Asia, accompanied by draconian legal measures in cases of drug trafficking.^1,2 The purpose of this study was to retrospectively evaluate the sensitivity, specificity and accuracy of plain abdominal digital radiography (DRL) for identifying the internal payloads of MA in “drug mules”.     

Multimodality imaging of obliterative portal venopathy: what every radiologist should know

Obliterative portal venopathy (OPV) is an important cause of non-cirrhotic portal hypertension, which is often erroneously misdiagnosed as cryptogenic cirrhosis. It has a worldwide distribution with majority of cases hailing from the Asian subcontinent. However, recently the disease has gained global attention particularly because of its association with human immunodeficiency virus infection and use of antiretroviral drug therapy (didanosine). As the name suggests, the disorder is characterized by sclerosis and obliteration of the intrahepatic portal vein branches (with attendant periportal fibrosis) leading to portal hypertension amid intriguingly little liver dysfunction. It primarily affects young adults who present with clinically significant portal hypertension in the form of episodes of variceal bleed; however, contrasting liver cirrhosis, the liver function and liver structure remain normal or near normal until late in the disease process. Radiological findings during advanced disease are often indistinguishable from cirrhosis often warranting a liver biopsy. Nevertheless, recent studies have suggested that certain imaging manifestations, if present, can help us to prospectively suggest the possibility of OPV. At imaging, OPV is characterized by a wide range of intrahepatic and/or extrahepatic portal venous abnormalities with attendant changes in liver and splenic volume and stiffness. We shall, through this pictorial review, appraise the literature and illustrate the germane radiological manifestations of OPV that can be seen using different imaging modalities including ultrasonography, CT, MRI, elastography and hepatic haemodynamic studies.It is important to recognize that not all varices mean liver cirrhosis. Although liver cirrhosis constitutes the commonest cause of portal hypertension, we should be aware that portal hypertension can occur in the absence of liver cirrhosis—a condition termed as non-cirrhotic portal hypertension (NCPH).^1,2 NCPH represents a heterogeneous group of (primarily vascular) disorders where portal hypertension manifests amid absent liver cirrhosis. Pathologically, the insult is either pre- or intrahepatic involving the main portal vein or its smaller branches and/or the perisinusoidal area.^1–3Obliterative portal venopathy (OPV) represents an important cause of NCPH that is characterized by sclerosis and obliteration of the medium-sized portal venous branches leading to portal hypertension.^1–10 Liver biopsy characteristically shows phlebosclerosis and periportal and perisinusoidal fibrosis amid absent cirrhosis (Figure 1).^1–3 Although, the exact aetiology is contentious, infections and prothrombotic states have been implicated in eastern and western patients, respectively.^1,2 Additionally, xenobiotic exposure, autoimmune and genetic factors have also been incriminated.^1–4 Although the disease has a worldwide distribution, it continues to remain poorly understood primarily owing to its relative rarity.^1–3,5–8 Another potential reason is the use of diverse terminologies under which the entity has been described from various parts of the globe, such as non-cirrhotic portal fibrosis in India, idiopathic portal hypertension in Japan and hepatoportal sclerosis in the USA.Open in a separate windowFigure 1.(a) Atrophic small portal tract (arrow) showing absent portal vein [haematoxylin and eosin stain (HE), ×200]. (b) Two small portal tract (arrows) approximations (×100, HE). (c) Portal and central vein approximation (×100, HE). (d) Parenchymal extinction suggested by portal–portal and portal–central approximation (Masson''s trichrome stain, ×200).More recently, the disease has gained global attention because of escalating number of cases being reported in human immunodeficiency virus (HIV)-infected patients.^1–3,8–10 Also, US Food and Drug Administration has recently issued a warning regarding the potential association of OPV in patients with HIV on didanosine (antiretroviral therapy).³OPV primarily affects young patients usually in their third or fourth decades of life. The affected individuals typically present with clinically significant portal hypertension characterized by multiple episodes of well-controlled upper gastrointestinal (GI) bleed, massive splenomegaly and/or hypersplenism.^1–3 Advanced stages of the disease are often indistinguishable from liver cirrhosis especially on imaging. However, discrimination from cirrhosis is crucial in clinical practice because of differences in management. Management of OPV is primarily symptomatic, that is, focused on management of an acute episode of variceal bleed. The risk of rebleeding and bleeding-related mortality is low. Intriguingly, in contrast to liver cirrhosis, the liver function and liver structure remain normal or near normal until late in the disease process leading to a better prognosis and higher survival rates; the 10-year survival rate is around 86–95%.^1,2 Development of jaundice, ascites and hepatic encephalopathy is uncommon and if at all is seen only after an episode of GI bleeding.^1,2 Liver failure and the incidence of developing hepatocellular carcinoma are also much lower.^1–3,8–10 Nonetheless, in 20–33% of patients, the liver gradually atrophies and shows functional decompensation, occasionally needing liver transplantation.^1,2Although limited literature is available on the radiological manifestations of OPV, recent studies have suggested certain imaging manifestations to be more prevalent in OPV that can allow discrimination from cirrhosis. Moreover, use of newer techniques, including transient elastography, can allow prospective non-invasive diagnosis of OPV based upon the differential changes in liver and splenic stiffness. The aim of this review is to appraise the imaging findings of OPV described in the literature and illustrate them across a wide array of imaging modalities, including ultrasonography, CT, MRI and elastography, in a group of biopsy-proven cases of OPV diagnosed at our institute.     

Value of diffusion-weighted imaging in the detection of viable tumour after neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer: comparison with T2 weighted and PET/CT imaging

Objectives

To evaluate the added value of diffusion-weighted imaging (DWI) in combination with T₂ weighted imaging (T2WI) compared with T2WI alone or positron emission tomography (PET)/CT for detecting viable tumour after neoadjuvant chemoradiation therapy (CRT) in patients with locally advanced rectal cancer.

Methods

50 consecutive patients with locally advanced rectal cancer (≥T3 or lymph node positive) who underwent neoadjuvant CRT and subsequent surgery were enrolled in this retrospective study. All patients underwent 3.0 T rectal MRI and PET/CT after completing CRT. For qualitative analysis, two radiologists independently reviewed T2WI alone and DWI with T2WI over a 1-month interval. One nuclear medicine physician reviewed PET/CT images using a five-point scale. Diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for detecting viable tumour were assessed. For quantitative analysis, the apparent diffusion coefficients (ADCs) of the lesions were measured and compared between the viable tumour group and non-viable tumour groups.

Results

For detecting viable tumours, DWI with T2WI improved diagnostic accuracies (Reviewer 1 detected 90%; Reviewer 2, 86%) over T2WI alone (Reviewer 1 detected 76%, p=0.5; Reviewer 2, 64%, p=0.013) or PET/CT (48%, p<0.001). The sensitivity of DWI with T2WI (Reviewer 1 detected 98%; Reviewer 2, 91%) was significantly higher than those of T2WI alone (Reviewer 1 detected 77%; Reviewer 2, 64%) or PET-CT (43%, p<0.05). Only for Reviewer 2 was the NPV of DWI with T2WI (43%) significantly different from that of PET/CT (17%, p<0.05). The specificities and PPVs of DWI with T2WI were not improved over those of T2WI alone or of PET/CT (both p>0.05). The mean ADC of the viable tumour group (0.93×10⁻³ mm² sc⁻¹) was significantly lower than that of the non-viable tumour group (1.55×10⁻³ mm² sc⁻¹, p<0.0001).

Conclusion

Adding DWI to T2WI is helpful for detecting viable tumours after neoadjuvant CRT compared with T2WI alone or PET/CT in patients with locally advanced rectal cancer.Neoadjuvant chemoradiation therapy (CRT) has now become the standard of care for clinically staged, locally advanced rectal cancer. This treatment is associated with fewer local recurrences [1] and may also result in improved long-term survival [2]. Post-operative histopathological results are important indicators of prognosis in rectal cancer after CRT [3,4]. Therefore, pre-operative and non-invasive assessment of response to CRT of rectal cancer, and the identification of viable tumours after CRT, are crucial for planning the most beneficial strategies for each individual patient. This could guide the optimisation of the surgical approach, perhaps indicating sphincter-saving surgery in deep-seated tumours or less aggressive resection in initially advanced tumours.Although MRI is considered the most accurate tool for primary tumour staging in rectal cancer [5-7], this modality has intrinsic limitations in the differentiation of residual viable tumour from surrounding fibrosis after neoadjuvant CRT of rectal cancer [8-10]. With the introduction of higher field-strength MR scanners and the parallel imaging technique for rectal MRI, diffusion-weighted imaging (DWI) has been shown to have several potential benefits for the assessment of tumour localisation and staging [11,12]. The usefulness of DWI at 1.5 T in measuring treatment response has been measured in several clinical studies [13-15]. Recently, 3.0 T MR scanners have become commercially available [16-18]; the increase in signal-to-noise ratio (SNR) provided by these machines offers increased DWI quality and improvements to apparent diffusion coefficient (ADC) maps.Aside from innovative MRI approaches such as DWI, non-invasive proof of tumour viability can be obtained using fluorine-18 fludeoxyglucose (¹⁸F-FDG) positron emission tomography (PET)/CT. Many investigators have reported a substantial decrease in standardised uptake value (SUV) post-CRT in responders compared with non-responders [19-22]. However, only a few studies have compared the abilities of MRI and PET/CT to enable prediction of responses to neoadjuvant CRT [23,24]. There has been no published comparative study of DWI and PET/CT in the evaluation of tumour viability after neoadjuvant CRT in locally advanced rectal cancer.Thus, the purpose of our study was to evaluate the added value of DWI in combination with T₂ weighted imaging (T2WI) compared with T2WI alone or PET/CT for detecting viable tumour after neoadjuvant CRT in patients with locally advanced rectal cancer.